MedPath

To compare the role of dexamethasone when given via different routes in preventing sore throat in patients after general anaesthesia.

Completed
Conditions
Patients posted for surgery under general anaesthesia
Registration Number
CTRI/2017/08/009524
Lead Sponsor
Shalini Sharma
Brief Summary

The study will be conducted at DRPGMC Tanda at Kangra. A total of 190 patients posted for surgery under general anaesthesia and requiring endotracheal intubation will be recruited. Dexamethasone will be administered to all the patients in equal doses but via different routes. Efficacy of different routes in preventing post operative sore throat and hoarseness will be assessed at 24 hours.

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
All
Target Recruitment
90
Inclusion Criteria
  • ASA 1,2 & 3 patients.
  • Age above 18.
  • Duration of surgery less than two hours.
Exclusion Criteria
  • Patients who are allergic to dexamethasone.
  • Anticipated difficult intubation.
  • Patients who need nasogastric tube.
  • Patients on steroids.
  • Patients with sore throat or hoarseness of voice.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
To compare the efficacy of equal dose of dexamethasone in preventing post anaesthesia sore throat and hoarseness when given via three different routes ie intravenous, nebulisation and after dipping the cuff before intubation.24 hourly till discharge.
Secondary Outcome Measures
NameTimeMethod
Requirement of analgesics in post operative period.Every 2 hourly till 24 hours.
Post operative nausea and vomiting.Every 2 hourly in the post operative period till 24 hours.

Trial Locations

Locations (1)

Dr. Rajendra Prasad govt. medical college Tanda.

🇮🇳

Kangra, HIMACHAL PRADESH, India

Dr. Rajendra Prasad govt. medical college Tanda.
🇮🇳Kangra, HIMACHAL PRADESH, India
Shalini Sharma
Principal investigator
9418011121
shalini.medico@gmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.